预约演示

更新于：2026-05-13

Naltrexone

纳曲酮

更新于：2026-05-13

概要

基本信息

简介纳曲酮是一种阿片受体拮抗剂，常用于治疗酒精和药物依赖症。VIVITROL是含有纳曲酮的药物，适用于在门诊环境下能够戒酒的酒精依赖症患者。在使用VIVITROL前，患者不应饮酒。此外，VIVITROL也适用于戒除阿片类药物后预防复发。使用VIVITROL时应该搭配心理社会支持一起实施。纳曲酮的作用机制为拮抗阿片受体中的μ、κ和δ受体。

药物类型

小分子化药

别名

DBR-LDN、Naltrexone implant、naltrexone implant(Drug Delivery Company)

+ [11]

靶点

Opioid receptors

作用方式

拮抗剂

作用机制

Opioid receptors拮抗剂(阿片样受体拮抗剂)

治疗领域

其他疾病消化系统疾病内分泌与代谢疾病+ [3]

在研适应症

鸦片依赖酗酒甲基苯丙胺滥用+ [11]

非在研适应症

获得性免疫缺陷综合征肢端雀斑恶性黑色素瘤酒精相关疾病+ [32]

原研机构

Alkermes, Inc.

在研机构

Alkermes, Inc.

Neurelis, Inc.

The Children's Mercy Hospital

+ [12]

非在研机构

The University of Chicago

University of Pennsylvania

National Institute on Alcohol Abuse & Alcoholism

+ [11]

权益机构

Statera Biopharma, Inc.

Aardvark Therapeutics, Inc.

Scilex Pharmaceuticals, Inc.

+ [9]

最高研发阶段批准上市

首次获批日期

美国 (2006-04-13),

酗酒

最高研发阶段(中国)终止

特殊审评孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C20H23NO4

InChIKeyDQCKKXVULJGBQN-XFWGSAIBSA-N

CAS号16590-41-3

关联

161

项与纳曲酮相关的临床试验

NCT07249554

/ Not yet recruiting临床2期IIT

Preliminary Safety and Efficacy of Semaglutide and Naltrexone Combination Therapy for Alcohol Use Disorder

This human laboratory study will collect preliminary safety and efficacy data from a sample of participants enrolled in a 4-week in-patient treatment program for alcohol use disorder.

开始日期2026-07-01

申办/合作机构

The Johns Hopkins University

NCT07064564

/ Not yet recruiting临床1期

A Randomized, Active-comparator Controlled, Two-Dose-level Study of iSTEP-N in Healthy Adults With Long Term Safety and PK Follow-up

This Phase 1b clinical study is evaluating iSTEP-N, an investigational extended-release implant containing naltrexone, a medication used to block the effects of opioids. The implant is placed under the skin of the thigh and is designed to release medication continuously over many months.
The main purpose of the study is to measure blood levels of naltrexone over time after administration of two different doses of the iSTEP-N implant and to compare those levels with the blood levels achieved by Vivitrol®, an FDA-approved injectable extended-release naltrexone given once every month.
The study will enroll healthy adult volunteers aged 18 to 65 years. Participants will be randomly assigned to one of three groups:
* Low-dose iSTEP-N implant
* High-dose iSTEP-N implant
* Monthly Vivitrol injections
Participants will be followed closely for approximately 12 months to measure medication levels and monitor safety, side effects, and overall health. The study will help determine whether the iSTEP-N implant can maintain naltrexone levels comparable to or higher than those achieved with monthly injections, especially during periods when protection from relapse is most important.
Participants who receive an iSTEP-N implant and still have detectable implant material or measurable medication levels at the end of the first year may continue in a long-term follow-up period lasting up to two additional years. During this period, researchers will monitor how long the implant remains detectable and how long medication continues to be released. If the implant remains after two years, participants may choose to have it surgically removed or simply end study participation.
The study is sponsored by Akyso Therapeutics, LLC, with clinical operations conducted at a dedicated clinical research center and oversight provided by an independent Institutional Review Board. All participants undergo screening examinations to confirm eligibility and are carefully monitored throughout participation.
Results from this study will help determine the appropriate dose of iSTEP-N for future clinical trials and support development of long-acting treatment options for opioid use disorder that may reduce the need for frequent injections.

开始日期2026-04-01

申办/合作机构

UAB Ardena

[+2]

NCT07269873

/ Not yet recruiting临床1期

A Sequential Dose Cohort Pharmacokinetic and Safety Study of Implantable Long-Acting Naltrexone Subcutaneous Pellets With or Without Bupropion Compared to Naltrexone IM Injection (Vivitrol®) in Healthy Normal Volunteers

Naltrexone (NTX), an opioid receptor antagonist, has a longstanding history of safe and effective use for the treatment of addictive disorders. NTX is available in several forms, such as daily oral tablets (Revia®) and sustained release monthly injections (Vivitrol®). BioCorRx Pharmaceuticals is currently developing a subcutaneous implantable pellet drug product, BICX104, which contains NTX base anhydrous (997.5 mg) and can be administered via a minor surgical procedure. BICX104 is anticipated to provide plasma concentrations of ≥ 1 ng/mL NTX for 3 months.
Subjects will be enrolled in 4 sequential cohorts and followed for a total of 196 days, comprising an 84-day treatment period, an 84-day follow-up period, and a 28-day post-treatment follow-up period. While therapeutic levels of naltrexone ( ≥ 1 ng/mL plasma concentration) are expected to be maintained throughout the treatment period, intermittent PK sampling will continue through Day 196, at which all subjects are expected to achieve NTX levels below the level of quantitation (BLQ). Safety parameters include assessment of adverse events, vital signs, laboratory parameters, ECG data, and the Columbia Suicide Severity Rating Scale (C-SSRS), and will continue through the final safety visit at Day 196.
A total of 30 healthy normal volunteers will be enrolled sequentially in the following cohorts, listed in sequence:
1. One BICX104 (1.0 g NTX) implantable pellet (n = 8)
2. One BICX104 implantable pellet with 450 mg QD bupropion XL (n = 8)
3. Two BICX104 implantable pellets with 450 mg QD bupropion XL (n = 8)
4. Three consecutive Vivitrol 380 mg injections Q28 days (n = 6) Enrollment will be stratified by biological sex (50% females and 50% males in each cohort)
Subjects will participate in 18 clinic visits over 31 weeks comprising the 3-week screening period, 12-week treatment period, 12-week follow-up period, and 4-week safety follow-up period.
The test products will be BICX104 implantable pellets (dosage: 1 or 2 implants q. 12 weeks), Bupropion XL (dosage: 450 mg QD)
BICX104 will be supplied to the clinical research site in appropriately labeled closed containers; bupropion XL will be supplied in its standard commercial packaging configuration.
The comparator product will be Vivitrol® IM injection (380 mg NTX) (dosage: 1 injection q. 4 weeks) Vivitrol® will be supplied in its standard commercial packaging configuration.
The study assessments will be as follows:
After all screening assessments and the 24-hour Treatment Initiation Visit, safety and PK assessments will occur on Days 3, 5, 7, 14, 21, 28, 42, 56, 70, 84, 98, 112, 126, 140, 154, and 168. Final safety assessments will occur on Day 196. The Treatment Initiation Visit will involve 1 overnight stay and include PK sampling at pre-dose, and 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 hours post-dose, in addition to safety assessments.
Safety assessments will include clinical chemistry, hematology, vital signs, physical exam, ECGs, and administration of the Columbia Suicide Severity Rating Scale (C-SSRS).

开始日期2026-01-13

申办/合作机构

BioCorRx Pharmaceuticals, Inc.

[+1]

100 项与纳曲酮相关的临床结果

登录后查看更多信息

100 项与纳曲酮相关的转化医学

登录后查看更多信息

100 项与纳曲酮相关的专利（医药）

登录后查看更多信息

8,719

项与纳曲酮相关的文献（医药）

2026-08-01·Journal of substance use and addiction treatment

Racial and ethnic differences in medications for opioid use disorder and overdose in 11 state Medicaid programs from 2016 to 2020

Article

作者: Tang, Lu ; Marks, Sarah ; Gifford, Katie ; Barnes, Andrew ; Gordon, Adam J ; Kim, Joo Yeon ; Essien, Utibe R ; Talbert, Jeffery ; Chang, Chung-Chou H ; Tossone, Krystel ; Mack, Aimee ; Hammerslag, Lindsey ; Cunningham, Peter ; Wilson, J Deanna ; Burns, Marguerite ; Cole, Evan S ; Roberts, Eric ; Allen, Lindsay ; Mohamoud, Shamis ; Junker, Stefanie ; Kennedy, Susan ; Donohue, Julie M ; Ware, Orrin ; Clark, Sarah ; Wang, Bill ; Austin, Anna ; Idala, David ; Fry, Carrie ; Ahrens, Katherine

INTRODUCTION:

Access to medications for opioid use disorder (MOUD) varies across racial and ethnic groups. As the largest payer for MOUD, Medicaid has potential to ensure access for all enrollees. We aimed to quantify recent trends and state variation in MOUD use by race and ethnicity in Medicaid.

METHODS:

Using a distributed research network, we conducted a cross-sectional study of 11 states' Medicaid data from 2016 to 2020. Among enrollees diagnosed with opioid use disorder (OUD), we measured the percent receiving MOUD (overall; and methadone, buprenorphine, naltrexone, separately), continuity of MOUD for ≥180 days, and claims-based overdose event rates. We estimated logistic regression models in each state with fixed effects for year, race/ethnicity, and year and race/ethnicity interaction terms to examine changes in demographic differences in outcomes over time, adjusting for patient characteristics. We pooled estimates using random effects meta-analyses.

RESULTS:

Of the 542,414 enrollees with OUD in 2020, 430,891 (79.4%) were non-Hispanic white, 77,952 (14.4%) were non-Hispanic Black, 17,094 (3.2%) were Hispanic, and 16,477 (3.0%) had other race or ethnicity. MOUD use increased among enrollees in all racial and ethnic groups over time. The share of non-Hispanic white enrollees diagnosed with OUD receiving MOUD increased from 52.3% to 68.8% from 2016 to 2020 while the percent of non-Hispanic Black enrollees receiving MOUD from 37.2% to 49.7% during that period. Differences were widest for buprenorphine versus methadone or naltrexone. In adjusted analyses, Hispanic and Non-Hispanic Black enrollees were less likely to receive MOUD (adjusted odds ratios (AOR) = 0.67 [95 CI 0.49-0.91] and AOR = 0.41 [95 CI 0.33-0.52], respectively) compared to non-Hispanic white enrollees in 2016. Differences in receipt of MOUD did not change from 2016 to 2020. Non-Hispanic Black enrollees were less likely to have continuous MOUD relative to non-Hispanic white enrollees (AOR = 0.68 [95 CI 0.61-0.77)]. Overdose events peaked in 2017 for all racial and ethnic groups and were highest for Hispanic enrollees in 2020.

CONCLUSION:

MOUD increased among all racial and ethnic groups in 11 state Medicaid programs from 2016 to 2020. Yet, racial and ethnic differences in MOUD persisted, especially for buprenorphine. Our findings can inform Medicaid efforts to improve access to MOUD for all enrollees affected by OUD.

2026-07-01·Journal of substance use and addiction treatment

Integrating addiction care in hepatology: Impact of liver consultation on post-discharge AUD treatment in alcohol-associated hepatitis

Article

作者: Cornet, Nicole ; Freedberg, Daniel ; Stoffel, Elina ; Lan, Nan ; Lin, Kevin

BACKGROUND:

Alcohol-associated hepatitis (AH) carries high short-term mortality and long-term morbidity. Current guidelines recommend that patients hospitalized with AH receive treatment for alcohol use disorder (AUD), including behavioral counseling and pharmacotherapy. However, integration of addiction treatment into routine inpatient care remains low. We evaluated whether inpatient hepatology consultation is associated with increased provision of AUD counseling and pharmacotherapy.

METHODS:

We conducted a retrospective cohort study of adults hospitalized with AH between January 2020 and July 2024 at a single academic center. AH was defined by ICD-10 code and NIAAA criteria. The primary exposure was liver service consultation. Primary outcomes were AUD counseling (dichotomized as referral provided vs. not) and pharmacotherapy (prescription vs. none). Multivariable logistic and mixed effects regression modeling was used to assess associations.

RESULTS:

There were 134 unique patients with 213 hospitalizations for AH. Median age was 47 years, 67% were male, and 73% were English-speaking. While nearly all patients (96%) received some form of counseling, only 17% were referred to structured rehabilitation programs and 30% received pharmacotherapy such as naltrexone, acamprosate, gabapentin and baclofen. In adjusted analyses, hepatology consultation (with or without GI involvement) was independently associated with higher odds of both referral to AUD treatment services (aOR 3.99, 95% CI 1.23-13.73 in a per-patient analysis and aOR 3.10, 95% CI 1.21-7.93 in a per-hospitalization analysis) and prescription of AUD pharmacotherapy (aOR 2.44, 95% CI 0.59-10.4 per-patient and aOR 3.74, 95% CI 1.16-12.06 per hospitalization).

CONCLUSIONS:

Despite hospitalization being a critical opportunity to initiate evidence-based AUD care, most patients with AH did not receive guideline-concordant treatment. Liver consultation services were associated with improved pharmacotherapy delivery and AUD referrals. Embedding addiction treatment protocols within hepatology pathways may improve delivery of AUD care and reduce disparities in this high-risk population.

2026-06-01·Addictive behaviors reports

Influence of residential greenness and season on discontinuation of medication treatment for opioid use disorder across rural to urban community types

Article

作者: Bandeen-Roche, Karen ; Schwartz, Brian S ; Nordberg, Cara M ; DeWalle, Joseph ; Poulsen, Melissa N ; Berrettini, Wade

Introduction:

Medications for opioid use disorder (MOUD) are standard of care for opioid use disorder (OUD), but high rates of treatment discontinuation limit their impact on recovery. Nature exposure and engagement holds promise as a potential adjunctive treatment to MOUD through stress reduction and mental health benefits. This study evaluated whether nature exposure influenced MOUD treatment participation by analyzing associations of residential greenness with MOUD discontinuation across a diverse geography in Pennsylvania, while considering interrelated factors-season and community type.

Methods:

We analyzed electronic health records from 2,570 adults receiving MOUD from an outpatient addiction treatment program. Weekly MOUD participation was derived from medication days' supply of buprenorphine or naltrexone. Average weekly greenness (normalized difference vegetation index) was assigned to buffers surrounding participants' residential address. We applied mixed-effects logistic regression of pooled person-weeks in treatment to model the odds of MOUD discontinuation, clustered by patient and with robust standard errors.

Results:

In models adjusted for sociodemographic factors, residential greenness was not associated with MOUD discontinuation. We observed associations of season with MOUD discontinuation: compared to spring weeks, the odds of MOUD discontinuation were 20-27% higher during summer, fall, and winter weeks. In season-stratified models, we observed a non-linear association of greenness and MOUD discontinuation during the spring season.

Conclusions:

Understanding factors contributing to MOUD discontinuation is essential to improving recovery outcomes for those with OUD. Findings suggest that passive greenness exposure may have little influence on MOUD participation but identified the potential importance of season on MOUD outcomes.

429

项与纳曲酮相关的新闻（医药）

2026-05-06

·allsci.com

Scilex spins off ACEA Pharma to Phoenix Asia Holdings in USD 1b all-stock transaction

Scilex Holding Company (Nasdaq: SCLX) has announced that its indirect subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., have entered into a stock acquisition agreement with Cayman Islands-incorporated Phoenix Asia Holdings Limited (Nasdaq: PHOE), under which Phoenix will acquire 100% of the issued and outstanding equity interests of ACEA Pharma in a transaction the parties have agreed to value at USD 1 billion. The deal provides ACEA Pharma with a path to an independent Nasdaq listing under the renamed entity ACEA Pharma, Inc., while separating the clinical-stage oncology, autoimmune, and COVID-19 portfolio from Scilex’s US-focused non-opioid pain management commercial operations. The consideration consists entirely of newly issued Phoenix ordinary shares: 100,000,000 shares at an agreed price of USD 10.00 per share, with no cash component, milestone payments, royalties, or contingent value rights disclosed. Upon closing, ACEA Therapeutics is expected to hold approximately 82% of the Go-Forward Company. No additional financial terms were disclosed. The transaction is subject to customary closing conditions, including applicable regulatory and stock exchange approvals, and is expected to close by the end of the second quarter of 2026. The boards of directors of ACEA Therapeutics, ACEA Pharma, and Phoenix have unanimously approved the transaction. ACEA Pharma is described as a clinical-stage company with a portfolio spanning cancer, autoimmune disease, and COVID-19, supported by drug manufacturing and commercial infrastructure in China through two operating subsidiaries: ACEA Pharmaceuticals in Quzhou and ACEA Pharma Research in Hangzhou. The press release does not name any individual drug candidate, development code, molecular target, or ClinicalTrials.gov identifier associated with the ACEA Pharma pipeline. ACEA also holds rights to develop and commercialize Ztlido (lidocaine topical system 1.8%) in Greater China and the ex-US Far East region under a collaboration with Scilex, an arrangement that passes to the Go-Forward Company upon closing. The absence of program-level disclosure means the most advanced ACEA asset cannot be determined from the available materials. The structure of the transaction is directly comparable to the 2026 reverse merger between Candid Therapeutics and Rallybio Corp. (Nasdaq: RLYB), in which a clinical-stage company used a Nasdaq-listed shell as a listing vehicle, with the operating company’s shareholders retaining approximately 96.3% of the combined entity. In both cases, the transaction achieves a public listing without a conventional IPO. The current deal also represents a significant revaluation relative to the 2021 acquisition of ACEA Therapeutics by Sorrento Therapeutics, which was completed at an implied value of approximately USD 38 million in Sorrento stock — a figure that contrasts with the USD 1 billion agreed valuation in the present transaction. For Scilex, the transaction separates the ACEA Pharma China-facing clinical and commercial platform from the company’s US commercial portfolio, which includes Ztlido, Elyxyb (celecoxib oral solution), and Gloperba (colchicine oral solution), alongside pipeline candidates SP-102, SP-103, and SP-104. Retaining approximately 82% of the Go-Forward Company allows Scilex to preserve economic exposure to the ACEA pipeline while establishing ACEA Pharma as an independently capitalized, publicly listed entity with direct access to equity markets. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

2026-05-05

·投医问药

The Lancet丨诺和诺德公布司美格鲁肽戒酒临床数据

点击蓝字关注我们投医问药 Summary 酒精使用障碍是全球重大公共卫生问题，每年约占全球死亡总数的5%，但目前FDA批准用于该病的药物仅有三种（戒酒硫、阿坎酸和纳曲酮），治疗效果十分有限。GLP-1受体激动剂影响大脑奖赏通路和食欲调节中枢，提示其在减少酒精摄入方面具有潜力，但此前在治疗寻求型酒精使用障碍患者中是否有效，尚不明确，且针对合并肥胖的该类人群的随机对照试验数据几乎空白。 2026年5月2日，哥本哈根精神卫生中心Anders Fink-Jensen等人在《The Lancet》发表题为"Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial"（每周一次semaglutide对比安慰剂治疗酒精使用障碍合并肥胖患者：一项随机、双盲、安慰剂对照试验）的研究论文。研究团队发现，在治疗寻求型酒精使用障碍合并肥胖患者中，每周皮下注射一次semaglutide（2.4 mg）与安慰剂相比，可显著减少重度饮酒天数（估计治疗差值–13.7个百分点，p=0.0015），并在多项酒精相关及躯体代谢指标上均呈现出实质性获益，不良事件以一过性轻中度胃肠道反应为主。欢迎关注公众号/设置星标并下载原文 01 ｜INTRODUCTION 酒精使用障碍是一种慢性复发性脑部疾病，以对酒精摄入失去控制和强迫性使用为特征。目前存在多种行为和心理治疗手段，认知行为治疗（CBT）是其中循证证据最为充分的方法之一。然而，尽管数十年来研究持续推进，FDA至今仅批准了三种药物——戒酒硫、阿坎酸和纳曲酮——用于该适应症，这凸显了对更有效治疗手段的迫切需求。GLP-1受体激动剂因已获批用于糖尿病和肥胖的治疗，近年来因其对大脑食欲调节和奖赏通路的作用而广受关注，提示其可能具有减少酒精摄入的潜力。重要的是，GLP-1受体激动剂总体耐受性良好，安全性特征优良，且由于其葡萄糖依赖性作用机制，低血糖风险极低。内源性GLP-1肽由小肠L细胞分泌，同时也在大脑中与奖赏和成瘾相关的区域合成。多种GLP-1受体激动剂在酒精成瘾动物模型中已显示出对酒精摄入、奖赏加工及复饮样行为的显著抑制作用，展现出稳健且令人期待的临床前结果。在人体研究中，基于真实世界数据库的研究发现，接受GLP-1受体激动剂治疗的糖尿病或肥胖患者中，酒精相关事件或酒精使用障碍的发生率更低。近期，一项纳入48例非治疗寻求型酒精使用障碍患者的随机对照试验——其特点是酒精使用障碍严重程度较低、相关后果较少、减少酒精摄入的主观意愿不强——给予低剂量semaglutide治疗2个月，结果显示在实验室酒精自我给药任务中酒精消耗量显著减少，并且与安慰剂相比，每次饮酒天数的饮酒量及酒精渴求度均有所下降。据研究团队所知，此前仅有一项随机对照试验评估了GLP-1受体激动剂（每周一次exenatide）在治疗寻求型酒精使用障碍患者中的作用，但总体上未发现重度饮酒天数的差异；探索性分析显示，exenatide能在BMI超过30 kg/m²的患者中减少酒精摄入；功能MRI子集分析亦发现，与安慰剂相比，exenatide治疗降低了奖赏相关脑区对酒精线索的反应性。基于上述背景，研究团队在治疗寻求型肥胖合并酒精使用障碍患者中开展了一项为期26周的随机对照试验，旨在探究GLP-1受体激动剂semaglutide（每周皮下注射2.4 mg）对酒精摄入的效果及安全性。 02 ｜RESULTS 研究共电话预筛302例患者，135例进入正式筛查，108例完成随机化（各组54例），88例（81%）完成全程干预。安慰剂组因多种原因（包括来自外部的semaglutide处方及自觉无效）脱落14例，semaglutide组脱落6例，两组间脱落时间无显著差异（HR=0.39，95% CI 0.15–1.01），整体样本量和完成率符合统计预设。图1. 试验流程图两组基线特征均衡：平均年龄52.3岁，女性占49%，平均重度饮酒天数17.2天，平均酒精摄入2200.9 g/30天，AUDIT平均评分22.8分，92%（85例）符合DSM-5重度酒精使用障碍标准，两组BMI均在33–35 kg/m²之间，提示研究人群具有代表性的重度饮酒和肥胖背景。表1. 基线特征 semaglutide组重度饮酒天数百分比较基线降低41.1个百分点，安慰剂组降低26.4个百分点，估计治疗差值为–13.7个百分点（95% CI –22.0至–5.4，p=0.0015）；总酒精摄入估计差值为–467.5 g/30天（p<0.0009）；酒精渴求（PACS评分）差值–3.1（p=0.0020）；体重差值–9.0 kg（p<0.0001）；γ-谷氨酰转移酶差值–24.2 U/L（p<0.0001），多项指标同步改善，证实semaglutide具有广泛的酒精相关及代谢获益。表2. 基线至第26周各终点变化研究团队通过时间-效应曲线展示了从基线至第26周两组重度饮酒天数百分比（A）和30天总酒精摄入量（B）的动态变化。semaglutide组在各随访时间点（第6、12、20、26周）的重度饮酒天数及总摄入量始终低于安慰剂组，且效果随时间延续而持续维持，未见疗效衰减，进一步确认了治疗效果的稳定性。图2. 每周一次semaglutide对比安慰剂在重度饮酒天数及总酒精摄入方面的疗效研究团队通过散点图展示，semaglutide组中体重减轻（均值约11.2 kg）与重度饮酒天数减少之间存在显著正相关（Spearman ρ=–0.40，p=0.0038），而安慰剂组未见此相关性（ρ=0.03，p=0.85），提示semaglutide对酒精摄入的抑制作用可能部分通过与体重/代谢调节共享的神经生物学通路介导。图3. 重度饮酒天数变化与体重减轻的相关性 semaglutide组最常见的不良事件为恶心（57% vs. 安慰剂组7%）、便秘（35% vs. 17%）、食欲下降（35% vs. 15%）及反流（28% vs. 2%），均为一过性且以轻中度为主；4例患者因胃肠道不良反应中止试验（semaglutide组）。semaglutide组唯一严重不良事件为1例腹痛住院（最低剂量0.25 mg时发生），未导致停药；整个试验期间未见胰腺炎事件，4例患者出现无症状淀粉酶升高（最高123 U/L）。表3. 严重不良事件、不良事件及不良反应 03 ｜DISCUSSION 本研究首次在治疗寻求型酒精使用障碍合并肥胖患者中证实，每周一次semaglutide（2.4 mg皮下注射）能够显著减少重度饮酒天数，并在多项酒精相关指标（总摄入量、每饮酒日饮酒量、酒精渴求、AUDIT评分、WHO饮酒风险等级）、酒精生物标志物（磷脂酰乙醇、γ-谷氨酰转移酶）及代谢指标（体重、BMI、腰围、HbA1c）上均显示出实质性获益，效应量处于中等水平（Cohen's d约0.45–0.57），且治疗所需数字（NNT）为4.3，优于现有FDA批准的酒精使用障碍药物（NNT≥7）。semaglutide组与体重减少显著相关的酒精摄入减少现象，提示其机制可能涉及肥胖与酒精使用障碍共享的神经生物学及代谢外周通路，但具体分子机制尚待阐明。本研究的局限性主要包括：入组标准限定BMI≥30 kg/m²，限制了结果向非肥胖酒精使用障碍人群的推广；单中心设计及以白人为主的研究人群影响结论的普适性；未收集第26周后的酒精随访数据，无法评估停药后效果的持续性；此外，基于psilocybin疗效研究进行的样本量估算使研究的统计效能设计存在一定局限。尽管如此，磷脂酰乙醇生物标志物的验证增强了自我报告酒精摄入数据的可靠性，结合semaglutide在肥胖合并酒精使用障碍这一庞大患病群体中展现的获益，以及GLP-1受体激动剂已有的安全记录，本研究为将semaglutide的适应症扩展至酒精使用障碍（尤其是合并肥胖者）提供了重要的临床证据支持，或将使全球数百万患者获益。 References [1] Mette Kruse Klausen, Signe Keller Justesen, Julie Niemann Pedersen, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. The Lancet, 2026; 407: 1687–98. https://doi.org/10.1016/S0140-6736(26)00305-3 [2] Rehm J, Assanangkornchai S, Hendershot CS, et al. Alcohol use disorders. Lancet, 2025; 406: 2269–81. [3] Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021; 384: 989–1002. [4] Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry, 2025; 82: 395–405. [5] Witkiewitz K, Anton RF, O'Malley SS, et al. Reductions in World Health Organization risk drinking levels as a primary efficacy end point for alcohol clinical trials: a review. JAMA Psychiatry, 2025; 82: 1246–54. [6] McPheeters M, O'Connor EA, Riley S, et al. Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis. JAMA, 2023; 330: 1653–65. [7] Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications, 2024; 15: 4548. [8] Leggio L, Farokhnia M, Kenny PJ, Pepino MY, Simmons WK. Crosstalk between alcohol use disorder and obesity: two sides of the same coin? Molecular Psychiatry, 2025; 30: 5938–52. [9] Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight, 2022; 7: e159863. [10] Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry, 2022; 79: 953–62. [11] Carroll KM, Kiluk BD. Cognitive behavioral interventions for alcohol and drug use disorders: through the stage model and back again. Psychology of Addictive Behaviors, 2017; 31: 847–61. 往期回顾【联合举办-清华大学生命科学学院行业大咖论坛】 ► 清华大学生命科学学院 “行业大咖讲坛”第一期晶泰科技赖力鹏 ► 清华大学生命科学学院 “行业大咖开讲”第二期迈威生物范梦奇【投医问药分享会】 ► 投医问药分享会第一期-脑转移肿瘤：基础科研、临床诊疗和成果转化（复旦大学迟喻丹；北医三院杨辰龙） ► 投医问药分享会第二期-细胞治疗（北京大学席建忠；北京科技研究院/海豚博士徐庞连；极客基因来威锋；清辉联诺马伟伟） ► 投医问药分享会第三期-AI+医药（晶泰科技赖力鹏；科迈生物黄小鲁；剂泰科技赖才达；数坤科技廖方舟；）【一文读懂系列】 ► Suzetrigine（镇痛/Nav1.8/VX-548） ► Efruxifermin（MASH/FGF21/Thrb） ► Penmenvy（/脑膜炎疫苗/MenABCWY） ► 全球首个iPS细胞疗法/日本干细胞监管政策【全球靶点在研管线一览】 ► CD3×BCMA×CD19► 双靶小核酸 ► GLP-1R×GIPR×GCGR ► TL1A单抗、双抗/多抗► miR-124 ► Kv7► ACVR2A/B ► amylin/AMYR► FGF21► Thr-β►VAP-1/SSAO►NTSR1 ► factor XI siRNA► GLP-1小分子激动剂►TRPC6►INHEBE ► TfR & CD98hc 单靶/双靶透脑递送管线►GPNMB-RYK 【新靶点】 ► 癌症新靶点:eSrc；GSH/GGT；GPX1；OSBPL8；Gstm2/3；mSWI/SNF；ACOD1；ADRB2-CXCL16；GPX4；U2AF1；CD161；NNMT；RAS-PI3Kα； ► 代谢新靶点:CLCC1；RANK；SLC25A45；Or5v1/Olfr110； ► 皮肤新靶点:OXGR1；SLIT2-ROBO2-EID1-EP300； ► 自免新靶点:TRPV3–IL-6/CCL20–GC；HLA-DR15；MLKL； ► 心脏/血液新靶点:αIIbβ3；p38； ► CGT新靶点:OR7A10；KLHL6； ► 抗衰老新靶点:cGAS-STING；Nr3c2；HIS-71、DOT-1.3； ► 纤维化新靶点:ROCK2；GLIS3； ► 再生医学新靶点:FGF9； ► 神经精神类新靶点:TREM2；SCAN；CRL5^SOCS4；SLC45A1；SLC45A4； ► 避孕新靶点:STK3；投医问药投医问药起源于清华大学、北京大学和中国科学院，包含投医问药分享会和投医问药俱乐部，以及与清华大学生命科学学院合办的行业大咖论坛等板块，为生物医药领域专业人士专门打造，通过小型圆桌论坛和分享会的形式，提供一个深度交流和合作的平台。俱乐部成员包括PI、博士后、博士生以及生物医药产业和金融界的专业人士。在这里，大家可以分享自己的研究成果，讨论科研转化的可能性，寻找合作伙伴和资本介入的机会。投医问药注重建立信任关系，保持公益性，为生物医药相关人士促成各类资源的精准匹配，促进科研成果、创业想法的转化和社会价值的实现。欢迎关注投医问药，并添加小编微信号：seekmedicine，添加微信时请备注：单位/职业/姓名，如果是PI/教授、创始人、合伙人等，还请注明。声明：本内容仅用作生物医药行业信息传播，不构成任何用药和投资建议。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系seekmedicine@163.com。点赞收藏分享

2026-05-05

·BioSpace

Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited

PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its indirect subsidiary, ACEA Therapeutics, Inc, an exempted company incorporated with limited liability in the Cayman Islands (“ACEA Thera”), ACEA Pharma, Inc., an exempted company incorporated with limited liability in the Cayman Islands and wholly owned subsidiary of ACEA Thera (“ACEA Pharma”), and Phoenix Asia Holdings Limited, a company organized under the laws of the Cayman Islands (“Phoenix”) (Nasdaq: PHOE), entered into a stock acquisition agreement pursuant to which ACEA Thera agreed to transfer and sell, and Phoenix agreed to purchase, 100% of the issued and outstanding equity interests of ACEA Pharma in exchange for the delivery to ACEA Thera of 100,000,000 newly-issued ordinary shares at $10.00 per share, par value $0.00001 per share, of Phoenix (the “Acquisition”), the value of which was as agreed by the parties to be $1,000,000,000. Upon the closing of the Acquisition, Phoenix will be renamed ACEA Pharma, Inc. (the “Go-Forward Company”), and its common stock is expected to be listed on The Nasdaq Stock Market LLC (“Nasdaq”). The boards of directors of ACEA Thera, ACEA Pharma and Phoenix have unanimously approved the proposed transaction. The closing of the Acquisition, which is expected to occur by the end of the second quarter of 2026, is subject to certain customary closing conditions, including applicable regulatory and stock exchange approval. Upon closing of the Acquisition, ACEA Thera anticipates that it will own approximately 82% of the Go-Forward Company. For more information on Scilex Holding Company, refer to For more information on Semnur Pharmaceuticals, Inc., refer to For more information on ZTlido ® including Full Prescribing Information, refer to . For more information on ELYXYB ® , including Full Prescribing Information, refer to . For more information on Gloperba ® , including Full Prescribing Information, refer to . info@scilexholding.com About Scilex Holding Company Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido ® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB ® , a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba ® , the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur Pharmaceuticals, Inc. (“Semnur”) (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia. Scilex is headquartered in Palo Alto, California. About ACEA Therapeutics, Inc. ACEA Therapeutics is a clinical stage pharmaceutical company with a diverse product portfolio to address unmet medical needs in cancer, autoimmune disease, and Covid-19. Alongside a robust R&D and clinical organization, ACEA has established drug manufacturing and commercial capabilities in China to support our long-term growth. This infrastructure provides us with greater control over our supply chain for timely delivery of highest quality products to patients. About Phoenix Asia Holdings Limited Phoenix Asia Holdings Limited is a company organized under the laws of the Cayman Islands. Phoenix Asia Holdings Limited operates as a holding company. Phoenix Asia Holdings Limited operates its business primarily through its indirectly wholly-owned operating subsidiary, Winfield Engineering (Hong Kong) Limited. Phoenix Asia Holdings Limited mainly engages in substructure works, such as site formation, ground investigation and foundation works, in Hong Kong. Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, statements regarding the proposed Acquisition, including the potential listing of the combined company on Nasdaq, the ability of the parties to successfully consummate the proposed Acquisition, and the timing of the closing of the proposed Acquisition. These statements are based on management’s current expectations and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business. These risks and uncertainties include, but are not limited to, the inability of the parties to consummate the proposed Acquisition for any reason, including any failure to satisfy or waive any closing conditions; changes in the structure, timing and completion of the proposed Acquisition; the combined company’s ability to gain approval to list its securities on Nasdaq upon closing of the proposed Acquisition; the ability of the parties to achieve the benefits of the proposed Acquisition, including future financial and operating results of the combined company; risks related to the outcome of any legal proceedings that may be instituted against the parties following the announcement of the proposed Acquisition; general economic, political and business conditions; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements. Contacts: Investors and Media Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 Office: (650) 516-4310 Email: investorrelations@scilexholding.com Website: SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned. ZTlido ® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba ® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company. ELYXYB ® is a registered trademark owned by Scilex Holding Company. Scilex Bio™ is a trademark owned by Scilex Holding Company. All other trademarks are the property of their respective owners. © 2026 Scilex Holding Company All Rights Reserved.

快速通道临床3期临床2期上市批准引进/卖出

100 项与纳曲酮相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
鸦片依赖	美国	Alkermes, Inc.	2010-10-12
酗酒	美国	Alkermes, Inc.	2006-04-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿片类药物过量	临床3期	美国	The University of California, San Francisco	2025-04-10
甲基苯丙胺滥用	临床3期	美国	National Institute on Drug Abuse	2024-07-01
甲基苯丙胺依赖	临床3期	美国	National Institute on Drug Abuse	2024-07-01
大便失禁	临床3期	美国	Yale University	2021-06-29
慢性盆腔疼痛综合征	临床3期	美国	Hershey Medical Center	2020-01-16
子宫内膜异位症	临床3期	美国	Hershey Medical Center	2020-01-16
暴食症	临床3期	美国	Yale University	2019-08-07
肥胖	临床3期	美国	Yale University	2019-08-07
阿片滥用	临床3期	美国	Alkermes, Inc.	2016-04-01
获得性免疫缺陷综合征	临床3期	美国	Yale University	2011-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05458609 (CTgov)	临床3期	酒精使用障碍	8	Lemborexant 10 mg+Naltrexone (Lemborexant Plus Naltrexone)	觸衊壓窪襯夢壓構醖襯(選醖繭鏇糧齋廠糧鏇膚) = 範鹹艱顧餘構製顧鑰窪淵鹹鑰襯顧膚繭鬱憲醖 (襯膚壓簾壓構壓艱願網, 16.77) 更多	-	2026-03-24
				Naltrexone (Placebo Plus Naltrexone)	觸衊壓窪襯夢壓構醖襯(選醖繭鏇糧齋廠糧鏇膚) = 淵膚範衊襯觸範範餘淵淵鹹鑰襯顧膚繭鬱憲醖 (襯膚壓簾壓構壓艱願網, 21.94) 更多
NCT03946111 (CTgov)	临床2/3期	暴食症 \| 肥胖	3	Naltrexone and Bupropion (Naltrexone/Bupropion)	憲構醖鏇鏇窪構廠選壓(網範獵襯壓壓襯鹹餘築) = 鹹糧壓襯網遞製衊願膚憲願願夢觸廠齋獵艱鬱 (餘憲衊糧鬱構衊醖選製, 0) 更多	-	2025-12-17
				Placebo (Placebo)	憲構醖鏇鏇窪構廠選壓(網範獵襯壓壓襯鹹餘築) = 膚蓋淵鹽製構選遞鹹築憲願願夢觸廠齋獵艱鬱 (餘憲衊糧鬱構衊醖選製, 18.38) 更多
NCT04817410 (CTgov)	临床1期	酒精使用障碍	30	Naltrexone (Oral Naltrexone)	糧製夢觸夢鹽糧淵顧願(蓋齋範壓齋觸鑰餘繭鬱) = 簾鹹積鬱夢窪糧遞願壓積鹽襯膚網構蓋廠繭憲 (淵製糧襯積遞鹽糧築選, 簾觸鹽襯衊夢餘網齋鏇 ~ 範積壓鬱鏇餘憲築觸淵) 更多	-	2025-08-26
				naltrexone (Enrolled Participant Characteristics)	襯衊艱顧窪餘醖鹽醖構(觸鬱鑰範憲夢齋鑰鬱壓) = 積繭鹽鏇淵襯衊蓋遞壓衊遞糧衊膚顧獵鬱窪選 (鹽夢鬱憲繭築簾範醖憲, 艱顧積選顧憲鬱齋構淵 ~ 鹽願構顧糧願艱鹹製廠) 更多
NCT02330419 (SayWhen, CTgov)	临床2期	HIV感染	120	Behavioral survey measurements: (Placebo)	衊願簾製糧獵憲選醖繭(簾壓願憲築廠膚艱齋艱) = 構艱餘糧遞糧簾膚顧齋蓋鏇窪構製構觸顧積夢 (選鑰齋窪夢構顧鬱憲廠, 鏇夢衊築獵憲鬱顧選壓 ~ 糧夢鏇鏇糧廠淵鬱艱糧) 更多	-	2025-04-20
				Behavioral survey measurements:+Naltrexone (Naltrexone)	衊願簾製糧獵憲選醖繭(簾壓願憲築廠膚艱齋艱) = 衊襯壓構觸鬱構膚遞範蓋鏇窪構製構觸顧積夢 (選鑰齋窪夢構顧鬱憲廠, 選積觸構窪鏇衊壓憲鑰 ~ 獵鏇鬱積齋築築鬱廠選) 更多
NCT01587196 (fMRI CURE, CTgov)	临床2期	-	72	Vivitrol	醖構觸顧艱窪鑰衊鬱餘 = 鹽餘夢顧醖獵築積蓋獵製築壓壓鹹餘繭醖憲艱 (獵衊壓繭積蓋繭壓膚願, 廠觸膚鏇艱觸顧齋觸蓋 ~ 淵範遞蓋廠願糧鏇鬱衊) 更多	-	2024-10-15
NCT04547985 (PGD, CTgov)	临床4期	-	9	Placebo (Placebo)	範蓋襯範糧鬱獵淵遞鬱(顧蓋醖艱築鹹鹹範襯夢) = 繭蓋選齋願鏇膚淵繭襯廠遞糧製願夢衊膚憲願 (窪膚齋夢網蓋鬱糧築遞, 7.36) 更多	-	2024-08-28
				Naltrexone HCl 50 MG Oral Tablet (Naltrexone)	範蓋襯範糧鬱獵淵遞鬱(顧蓋醖艱築鹹鹹範襯夢) = 憲廠窪築遞鹽衊廠遞壓廠遞糧製願夢衊膚憲願 (窪膚齋夢網蓋鬱糧築遞, NA) 更多
DDW 12024 \| DDW 22024 \| DDW 32024 \| DDW 42024	N/A	酒精性肝疾病	-	Naltrexone	醖鑰願製鹽壓壓遞築齋(獵製範範餘顧鑰鹽簾糧) = the rate of AUD medication discontinuation for adverse events was similar in both groups (14% vs 12%) and none were stopped due to suspected DILI 願顧選鹽齋鑰餘觸鏇簾 (餘廠窪選網築糧簾襯構 ) 更多	-	2024-05-20
				Acamprosate
DDW 12024 \| DDW 22024 \| DDW 32024 \| DDW 42024	N/A	酒精性肝疾病	-	Naltrexone	醖夢鹹鑰餘醖獵築顧襯(醖繭願膚選窪繭繭窪艱) = 簾鹹糧壓繭網範獵製淵選繭遞鑰製遞獵醖淵襯 (製艱構衊衊齋鑰顧齋壓 )	-	2024-05-20
				Acamprosate	醖夢鹹鑰餘醖獵築顧襯(醖繭願膚選窪繭繭窪艱) = 範襯製齋膚廠簾網構糧選繭遞鑰製遞獵醖淵襯 (製艱構衊衊齋鑰顧齋壓 )
NCT02885311 (CTgov)	临床1/2期	酗酒 \| 酒精相关疾病	27	Brief Advice (At-Risk Drinkers (AR))	築繭糧鑰鑰艱築廠夢構(鹹繭選範醖範製鹽願鬱) = 糧膚襯鹽選鏇膚醖鏇壓鹹壓齋夢遞鏇衊夢鬱窪 (網襯襯廠鹽齋夢鹹窪壓, 4.1) 更多	-	2023-10-30
				Brief Advice+Naltrexone (Problem Drinkers (PD))	築繭糧鑰鑰艱築廠夢構(鹹繭選範醖範製鹽願鬱) = 鹹襯願夢壓窪膚壓網鏇鹹壓齋夢遞鏇衊夢鬱窪 (網襯襯廠鹽齋夢鹹窪壓, 8.0) 更多
NCT04249882 (CTgov)	临床2期	酒精使用障碍	53	Placebo (Placebo)	窪廠觸淵鑰網壓膚蓋鏇(壓蓋獵襯蓋製蓋選壓簾) = 遞網艱鏇艱積糧艱網鑰簾製衊願顧網鏇膚餘鑰 (顧繭網壓鑰繭襯積築衊, 6.67) 更多	-	2023-09-14
				Varenicline (Varenicline)	窪廠觸淵鑰網壓膚蓋鏇(壓蓋獵襯蓋製蓋選壓簾) = 壓襯餘願醖餘鑰憲衊選簾製衊願顧網鏇膚餘鑰 (顧繭網壓鑰繭襯積築衊, 6.87) 更多